NEW YORK, August 5, 2026
Lexeo Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to LX2020, the company’s investigational AAV-based gene therapy for PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM). The designation is supported by interim clinical data from the ongoing HEROIC-PKP2 Phase I/II trial and provides enhanced regulatory interactions with the FDA, including the potential for accelerated approval, priority review, and rolling review. LX2020 now holds RMAT, Fast Track, and Orphan Drug designations, strengthening its regulatory pathway as a potential one-time disease-modifying therapy for a serious inherited cardiovascular disorder with no approved disease-modifying treatment.
Interim Clinical Data Strengthens Regulatory Momentum
The RMAT designation reflects encouraging interim findings from the ongoing HEROIC-PKP2 Phase I/II clinical trial, which is evaluating LX2020 in patients with PKP2-ACM, a progressive inherited heart disease caused by mutations in the PKP2 gene. According to Lexeo Therapeutics, the therapy is designed to systemically deliver a functional full-length PKP2 gene using the AAVrh10 viral vector, restoring the desmosomal complex and improving cell-to-cell adhesion in cardiomyocytes. Company executives stated that the designation enables closer collaboration with the FDA on clinical development, manufacturing, and potential approval pathways while supporting the advancement of the gene therapy toward later-stage development.
LX2020 Targets the Genetic Cause of a Rare Heart Disease
PKP2-associated arrhythmogenic cardiomyopathy accounts for approximately 50% of all arrhythmogenic cardiomyopathy cases and is estimated to affect around 60,000 people in the United States. The disease can lead to heart muscle damage, fibrosis, dangerous arrhythmias, heart failure, and sudden cardiac death. LX2020 is being evaluated as a one-time gene therapy designed to address the underlying genetic defect rather than only managing symptoms. By restoring normal PKP2 protein expression, the investigational therapy aims to prevent disease progression and improve long-term cardiac function in affected patients.
Advertisement
Lexeo Expands Leadership in Cardiovascular Gene Therapy
Lexeo Therapeutics continues to strengthen its cardiovascular gene therapy pipeline through regulatory advancements for LX2020, alongside other clinical programs targeting rare genetic heart diseases. The FDA’s RMAT designation marks an important milestone that may accelerate development and future regulatory review while reinforcing confidence in the company’s genetic medicine platform. Lexeo plans to provide additional clinical and regulatory updates before the end of 2026, as it advances LX2020 toward becoming a potential first disease-modifying gene therapy for PKP2-associated arrhythmogenic cardiomyopathy.
Source: Lexeo Therapeutics, press release
